How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias.

Pharmacoepidemiol Drug Saf 2019 Jan 15. Epub 2019 Jan 15.

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada.

Several pharmacoepidemiology networks have been developed over the past decade that use a distributed approach, implementing the same analysis at multiple data sites, to preserve privacy and minimize data sharing. Distributed networks are efficient, by interrogating data on very large populations. The structure of these networks can also be leveraged to improve replicability, increase transparency, and reduce bias. We describe some features of distributed networks using, as examples, the Canadian Network for Observational Drug Effect Studies, the Sentinel System in the USA, and the European Research Network of Pharmacovigilance and Pharmacoepidemiology. Common protocols, analysis plans, and data models, with policies on amendments and protocol violations, are key features. These tools ensure that studies can be audited and repeated as necessary. Blinding and strict conflict of interest policies reduce the potential for bias in analyses and interpretation. These developments should improve the timeliness and accuracy of information used to support both clinical and regulatory decisions.

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pds.4722
Publisher Site
http://dx.doi.org/10.1002/pds.4722DOI Listing
January 2019
4 Reads

Publication Analysis

Top Keywords

improve replicability
8
distributed networks
8
pharmacoepidemiology networks
8
european network
4
usa european
4
sentinel system
4
network pharmacovigilance
4
system usa
4
pharmacoepidemiology common
4
plans data
4
data models
4
analysis plans
4
protocols analysis
4
studies sentinel
4
common protocols
4
pharmacovigilance pharmacoepidemiology
4
observational drug
4
transparency reduce
4
reduce bias
4
increase transparency
4

Similar Publications